Platelet adhesion to decorin but not collagen I correlates with the integrin  2 dimorphism E534K, the basis of the human platelet alloantigen (HPA)-5 system

Kunicki, Thomas J.; Williams, Shirley; Díaz, Daniel; Farndale, Richard W.; Nugent, Diane J.

doi:10.3324/haematol.2011.056556

Cited by 6 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 69 The risk of appearance of pleural effusion in dasatinib treated patients does not seem to decrease with time. 88 Besides, recurrence of pleural effusion occurs in roughly 70% of the cases. However, most of the pleural effusions are mild or moderate, with grade 3/4 reported in 4% 19 and low rates of dasatinib discontinuation due to this side effect during the first year.…”

Section: Specific Systemsmentioning

confidence: 99%

“…In second-line treatment with dasatinib, the median time to appearance is 5–11 months, 89 , 90 but it can be delayed until 3 years. 91 In first-line use, the median time to pleural effusion was 10 months, and most effusions (89%) occurred more than 8 weeks into treatment; 88 although the risk diminishes with time, pleural effusion can occur throughout treatment. 35…”

Section: Specific Systemsmentioning

confidence: 99%

See 1 more Smart Citation

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Baccarani²,

et al. 2016

View full text Add to dashboard Cite

Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors (TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast, adverse events (AEs) are often reported as infrequent, minor, tolerable and manageable, but they are increasingly important as therapy is potentially lifelong and multiple TKIs are available. For this reason, the European LeukemiaNet panel for CML management recommendations presents an exhaustive and critical summary of AEs emerging during CML treatment, to assist their understanding, management and prevention. There are five major conclusions. First, the main purpose of CML treatment is the antileukemic effect. Suboptimal management of AEs must not compromise this first objective. Second, most patients will have AEs, usually early, mostly mild to moderate, and which will resolve spontaneously or are easily controlled by simple means. Third, reduction or interruption of treatment must only be done if optimal management of the AE cannot be accomplished in other ways, and frequent monitoring is needed to detect resolution of the AE as early as possible. Fourth, attention must be given to comorbidities and drug interactions, and to new events unrelated to TKIs that are inevitable during such a prolonged treatment. Fifth, some TKI-related AEs have emerged which were not predicted or detected in earlier studies, maybe because of suboptimal attention to or absence from the preclinical data. Overall, imatinib has demonstrated a good long-term safety profile, though recent findings suggest underestimation of symptom severity by physicians. Second and third generation TKIs have shown higher response rates, but have been associated with unexpected problems, some of which could be irreversible. We hope these recommendations will help to minimise adverse events, and we believe that an optimal management of them will be rewarded by better TKI compliance and thus better CML outcomes, together with better quality of life.

show abstract

Section: Specific Systemsmentioning

confidence: 99%

Section: Specific Systemsmentioning

confidence: 99%

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Baccarani²,

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The integrin α2β1 (VLA-2; GPIa-IIa, CD49b) is widely expressed on numerous cell types and binds specifically to type I collagen and decorin [1], [2], but also to collagens types II-V and laminins 1 and 5 [3]. The α2 protein was first isolated from platelets where it mediates adhesion to extracellular matrix collagen and contributes to the initiation of platelet activation and hemostasis [4], [5].…”

Section: Introductionmentioning

confidence: 99%

Conditional Knockout of Integrin α2β1 in Murine Megakaryocytes Leads to Reduced Mean Platelet Volume

et al. 2013

View full text Add to dashboard Cite

We have engineered a transgenic mouse on a C57BL/6 background that bears a floxed Itga2 gene. The crossing of this mouse strain to transgenic mice expressing Cre recombinase driven by the megakaryocyte (MK)-specific Pf4 promoter permits the conditional knockout of Itga2 in the MK/platelet lineage. Mice lacking MK α2β1 develop normally, are fertile, and like their systemic α2β1 knockout counterparts, exhibit defective adhesion to and aggregation induced by soluble type I collagen and a delayed onset to low dose fibrillar collagen-induced aggregation, results consistent with blockade or loss of platelet α2β1. At the same time, we observed a significant reduction in mean platelet volume, which is consistent with the reported role of α2β1 in MK maturation and proplatelet formation in vivo. This transgenic mouse strain bearing a floxed Itga2 gene will prove valuable to distinguish in vivo the temporal and spatial contributions of α2 integrin in selected cell types.

show abstract

Gene Polymorphisms and Signaling Defects

Mannhalter

Poteser

2013

Interdisciplinary Concepts in Cardiovascular Health

View full text Add to dashboard Cite

Platelet adhesion to decorin but not collagen I correlates with the integrin 2 dimorphism E534K, the basis of the human platelet alloantigen (HPA)-5 system

Cited by 6 publications

References 24 publications

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Conditional Knockout of Integrin α2β1 in Murine Megakaryocytes Leads to Reduced Mean Platelet Volume

Gene Polymorphisms and Signaling Defects

Contact Info

Product

Resources

About